AMI Asset Management Corp Sells 16,258 Shares of Zoetis Inc. $ZTS

AMI Asset Management Corp trimmed its position in Zoetis Inc. (NYSE:ZTS) by 5.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 285,894 shares of the company’s stock after selling 16,258 shares during the quarter. Zoetis accounts for 2.0% of AMI Asset Management Corp’s portfolio, making the stock its 20th largest position. AMI Asset Management Corp owned about 0.06% of Zoetis worth $35,971,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Halbert Hargrove Global Advisors LLC raised its stake in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. Global Wealth Strategies & Associates acquired a new position in Zoetis during the fourth quarter worth $25,000. Lodestone Wealth Management LLC acquired a new position in Zoetis during the fourth quarter worth $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis during the third quarter worth $31,000. Finally, Holos Integrated Wealth LLC acquired a new position in Zoetis during the fourth quarter worth $32,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $120.08 on Tuesday. Zoetis Inc. has a twelve month low of $113.29 and a twelve month high of $172.23. The firm has a market cap of $50.51 billion, a PE ratio of 19.95, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The business has a fifty day moving average of $122.12 and a 200-day moving average of $126.90.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Piper Sandler reiterated a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Morgan Stanley set a $160.00 price objective on Zoetis in a research note on Thursday, December 18th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.